Extended Release Drugs Market

Jun 2022| FMI1798A| Future Markets Insights

Report Highlights

Extended Release Drugs: Market Insights

Drug delivery systems are engineered technologies for controlled release of drugs or to the targeted delivery of drugs. Drug delivery system is a kind of formulation that enables the administration of therapeutic agents in the body and improves its safety and efficacy by controlling the time, rate and place of drug release in the body. Most of the conventional oral products of drugs are formulated to release the active ingredient as soon as it is administered. Now the pattern has been changed to modified release dosage forms to achieve better therapeutic target. Extended release drugs is a type of dosage forms which allows a two-fold reduction in frequency of dosage administered in the body. FDA has enabled certain guidelines for the extended release drugs such as notification in changing the safety labelling of extended release drugs.

Extended Release Drugs: Market Dynamics

Extended release drugs is likely to trigger growth in the market owing to increasing acceptance of different dosage forms, growing pediatric and geriatric population is likely to witness significant growth in the market. Moreover increasing research and development and ongoing clinical trials seems to spur the growth of the extended release drugs market. Also increasing focus in innovation and development of novel therapeutics adds another factor in increasing the growth of the extended release drugs market. However, there are certain limitation that may hamper the growth of the market such as cost of the extended release drugs. For example, Namenda extended release drugs cost around US$ 494 for 7mg. Apart from this, extended release drugs have a have a slower onset of action and may cause potential side effects. All this factors is likely to hamper the growth of the extended release drugs market.

Extended Release Drugs Market: Segmentation

The global extended release drugs market is segmented by drug release types and distributional channel

Extended Release Drugs Market Segmentation by Drug Release

  • Sustained Release
  • Controlled Release

Extended Release Drugs Market Segmentation by Distributional Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Mail Order Pharmacies
  • Drug Stores

Extended Release Drugs Market: Overview

Extended release drugs is expected to anticipate significant growth in the market. Manufacturers are currently focus in developing drugs that actively acts on the target. Various extended release drugs has been approved by FDA for the treatment chronic diseases such as Opana ER by Endo Pharmaceuticals, Nucynta ER by Janssen Pharmaceuticals, Exalgo by Mallinckrodt, Fentanyl by Actavis, Avinza by Pfizer etc. Extended release drugs mostly include special coating that make the drug to stay for a longer period of time. Extended release drugs is mostly used to prevent from chronic pain and other diseases. Thus, with increasing prevalence, the extended release drugs will boost the growth of the market.

Extended Release Drugs: Region-wise Outlook

On the basis of geography, the global extended release drugs market is segmented into seven key regions: North America, Latin America, Western Europe, Eastern Europe, and Asia Pacific excluding Japan and Middle East & Africa. North America holds significant revenue share in the extended release drugs market due to rising adoption of novel therapeutics and growing investments in research and development will propel the growth of extended release drugs market. Europe market witness to trigger the growth of the extended release drugs market due to significant rise in prevalence of chronic diseases such as cancer, COPD, diabetes etc. and increasing approval of novel drugs will boost the growth of the extended release drugs market. Asia Pacific also have the potential in fostering the growth of the extended release drugs market due to increasing pharmaceutical companies in development of various diseases. Japan seems to have significant potential to grow in the overall extended release drugs market due to growing number of geriatric population. Middle East & Africa have relatively less growth in extended release drugs market due to lack of investment in research and development and low economy growth which as a result will hinder the growth of the extended release drugs market.

Extended Release Drugs Market: Key Players

Some of the key players present across the value chain of the global extended release drugs market are Pfizer, Mallinckrodt, Actavis, Janssen Pharmaceuticals, Endo Pharmaceuticals, Purdue Pharma, Lavipharm Labs, Mylan Technologies, Noven, Aveva, Watson, Impax, Ranbaxy and others

The report covers exhaustive analysis on:

  • Market Segments
  • Market Dynamics
  • Market Size
  • Current Trends/Issues/Challenges
  • Competition & Companies involved
  • Value Chain

The regional analysis includes:

  • North America (U.S., Canada)
  • Latin America (Mexico. Brazil)
  • Western Europe (Germany, Italy, France, U.K, Spain, Nordic countries, Belgium, Netherlands, Luxembourg)
  • Eastern Europe (Poland, Russia)
  • Asia-Pacific Excluding Japan (China, India, ASEAN, Australia & New Zealand)
  • Japan
  • The Middle East and Africa (GCC, S. Africa, N. Africa)

The report is a compilation of first-hand information, qualitative and quantitative assessment by industry analysts, inputs from industry experts and industry participants across the value chain. The report provides in-depth analysis of parent market trends, macroeconomic indicators and governing factors along with market attractiveness as per segments. The report also maps the qualitative impact of various market factors on market segments and geographies.

Report Synopsis

Report Metrics Details
Base year considered 2022
Forecast period considered 2022-2032
Units considered $ Million
Segments covered By Drug Release, By Distributional Channel, By Region
Industry covered Healthcare
Countries covered North America, Latin America, Europe, East Asia, South Asia & Pacific, Middle East and Africa
Companies studied
  • Pfizer
  • Janssen Pharmaceuticals
  • Mallinckrodt
  • Actavis
  • Lavipharm Labs
  • Endo Pharmaceuticals
  • Purdue Pharma
  • Watson
  • Mylan Technologies
  • Noven
  • Aveva
  • Impax
  • Ranbaxy

Report Highlights:

  • Detailed overview of parent market
  • Changing market dynamics in the industry
  • In-depth market segmentation
  • Historical, current and projected market size in terms of volume and value
  • Recent industry trends and developments
  • Competitive landscape
  • Strategies of key players and products offered
  • Potential and niche segments, geographical regions exhibiting promising growth
  • A neutral perspective on market performance

NOTE - All statements of fact, opinion, or analysis expressed in reports are those of the respective analysts. They do not necessarily reflect formal positions or views of Future Market Insights.

  • Table 1 : Global Market Value (US$ Million) Forecast by Region, 2017 to 2032
  • Table 2 : Global Market Volume (Tons) Forecast by Region, 2017 to 2032
  • Table 3 : Global Market Value (US$ Million) Forecast by Drug Release, 2017 to 2032
  • Table 4 : Global Market Volume (Tons) Forecast by Drug Release, 2017 to 2032
  • Table 5 : Global Market Value (US$ Million) Forecast by Distributional Channel, 2017 to 2032
  • Table 6 : Global Market Volume (Tons) Forecast by Distributional Channel, 2017 to 2032
  • Table 7 : North America Market Value (US$ Million) Forecast by Country, 2017 to 2032
  • Table 8 : North America Market Volume (Tons) Forecast by Country, 2017 to 2032
  • Table 9 : North America Market Value (US$ Million) Forecast by Drug Release, 2017 to 2032
  • Table 10 : North America Market Volume (Tons) Forecast by Drug Release, 2017 to 2032
  • Table 11 : North America Market Value (US$ Million) Forecast by Distributional Channel, 2017 to 2032
  • Table 12 : North America Market Volume (Tons) Forecast by Distributional Channel, 2017 to 2032
  • Table 13 : Latin America Market Value (US$ Million) Forecast by Country, 2017 to 2032
  • Table 14 : Latin America Market Volume (Tons) Forecast by Country, 2017 to 2032
  • Table 15 : Latin America Market Value (US$ Million) Forecast by Drug Release, 2017 to 2032
  • Table 16 : Latin America Market Volume (Tons) Forecast by Drug Release, 2017 to 2032
  • Table 17 : Latin America Market Value (US$ Million) Forecast by Distributional Channel, 2017 to 2032
  • Table 18 : Latin America Market Volume (Tons) Forecast by Distributional Channel, 2017 to 2032
  • Table 19 : Europe Market Value (US$ Million) Forecast by Country, 2017 to 2032
  • Table 20 : Europe Market Volume (Tons) Forecast by Country, 2017 to 2032
  • Table 21 : Europe Market Value (US$ Million) Forecast by Drug Release, 2017 to 2032
  • Table 22 : Europe Market Volume (Tons) Forecast by Drug Release, 2017 to 2032
  • Table 23 : Europe Market Value (US$ Million) Forecast by Distributional Channel, 2017 to 2032
  • Table 24 : Europe Market Volume (Tons) Forecast by Distributional Channel, 2017 to 2032
  • Table 25 : East Asia Market Value (US$ Million) Forecast by Country, 2017 to 2032
  • Table 26 : East Asia Market Volume (Tons) Forecast by Country, 2017 to 2032
  • Table 27 : East Asia Market Value (US$ Million) Forecast by Drug Release, 2017 to 2032
  • Table 28 : East Asia Market Volume (Tons) Forecast by Drug Release, 2017 to 2032
  • Table 29 : East Asia Market Value (US$ Million) Forecast by Distributional Channel, 2017 to 2032
  • Table 30 : East Asia Market Volume (Tons) Forecast by Distributional Channel, 2017 to 2032
  • Table 31 : South Asia & Pacific Market Value (US$ Million) Forecast by Country, 2017 to 2032
  • Table 32 : South Asia & Pacific Market Volume (Tons) Forecast by Country, 2017 to 2032
  • Table 33 : South Asia & Pacific Market Value (US$ Million) Forecast by Drug Release, 2017 to 2032
  • Table 34 : South Asia & Pacific Market Volume (Tons) Forecast by Drug Release, 2017 to 2032
  • Table 35 : South Asia & Pacific Market Value (US$ Million) Forecast by Distributional Channel, 2017 to 2032
  • Table 36 : South Asia & Pacific Market Volume (Tons) Forecast by Distributional Channel, 2017 to 2032
  • Table 37 : MEA Market Value (US$ Million) Forecast by Country, 2017 to 2032
  • Table 38 : MEA Market Volume (Tons) Forecast by Country, 2017 to 2032
  • Table 39 : MEA Market Value (US$ Million) Forecast by Drug Release, 2017 to 2032
  • Table 40 : MEA Market Volume (Tons) Forecast by Drug Release, 2017 to 2032
  • Table 41 : MEA Market Value (US$ Million) Forecast by Distributional Channel, 2017 to 2032
  • Table 42 : MEA Market Volume (Tons) Forecast by Distributional Channel, 2017 to 2032
  • Figure 1 : Global Market Value (US$ Million) by Drug Release, 2022 to 2032
  • Figure 2 : Global Market Value (US$ Million) by Distributional Channel, 2022 to 2032
  • Figure 3 : Global Market Value (US$ Million) by Region, 2022 to 2032
  • Figure 4 : Global Market Value (US$ Million) Analysis by Region, 2017 to 2032
  • Figure 5 : Global Market Volume (Tons) Analysis by Region, 2017 to 2032
  • Figure 6 : Global Market Value Share (%) and BPS Analysis by Region, 2022 to 2032
  • Figure 7 : Global Market Y-o-Y Growth (%) Projections by Region, 2022 to 2032
  • Figure 8 : Global Market Value (US$ Million) Analysis by Drug Release, 2017 to 2032
  • Figure 9 : Global Market Volume (Tons) Analysis by Drug Release, 2017 to 2032
  • Figure 10 : Global Market Value Share (%) and BPS Analysis by Drug Release, 2022 to 2032
  • Figure 11 : Global Market Y-o-Y Growth (%) Projections by Drug Release, 2022 to 2032
  • Figure 12 : Global Market Value (US$ Million) Analysis by Distributional Channel, 2017 to 2032
  • Figure 13 : Global Market Volume (Tons) Analysis by Distributional Channel, 2017 to 2032
  • Figure 14 : Global Market Value Share (%) and BPS Analysis by Distributional Channel, 2022 to 2032
  • Figure 15 : Global Market Y-o-Y Growth (%) Projections by Distributional Channel, 2022 to 2032
  • Figure 16 : Global Market Attractiveness by Drug Release, 2022 to 2032
  • Figure 17 : Global Market Attractiveness by Distributional Channel, 2022 to 2032
  • Figure 18 : Global Market Attractiveness by Region, 2022 to 2032
  • Figure 19 : North America Market Value (US$ Million) by Drug Release, 2022 to 2032
  • Figure 20 : North America Market Value (US$ Million) by Distributional Channel, 2022 to 2032
  • Figure 21 : North America Market Value (US$ Million) by Country, 2022 to 2032
  • Figure 22 : North America Market Value (US$ Million) Analysis by Country, 2017 to 2032
  • Figure 23 : North America Market Volume (Tons) Analysis by Country, 2017 to 2032
  • Figure 24 : North America Market Value Share (%) and BPS Analysis by Country, 2022 to 2032
  • Figure 25 : North America Market Y-o-Y Growth (%) Projections by Country, 2022 to 2032
  • Figure 26 : North America Market Value (US$ Million) Analysis by Drug Release, 2017 to 2032
  • Figure 27 : North America Market Volume (Tons) Analysis by Drug Release, 2017 to 2032
  • Figure 28 : North America Market Value Share (%) and BPS Analysis by Drug Release, 2022 to 2032
  • Figure 29 : North America Market Y-o-Y Growth (%) Projections by Drug Release, 2022 to 2032
  • Figure 30 : North America Market Value (US$ Million) Analysis by Distributional Channel, 2017 to 2032
  • Figure 31 : North America Market Volume (Tons) Analysis by Distributional Channel, 2017 to 2032
  • Figure 32 : North America Market Value Share (%) and BPS Analysis by Distributional Channel, 2022 to 2032
  • Figure 33 : North America Market Y-o-Y Growth (%) Projections by Distributional Channel, 2022 to 2032
  • Figure 34 : North America Market Attractiveness by Drug Release, 2022 to 2032
  • Figure 35 : North America Market Attractiveness by Distributional Channel, 2022 to 2032
  • Figure 36 : North America Market Attractiveness by Country, 2022 to 2032
  • Figure 37 : Latin America Market Value (US$ Million) by Drug Release, 2022 to 2032
  • Figure 38 : Latin America Market Value (US$ Million) by Distributional Channel, 2022 to 2032
  • Figure 39 : Latin America Market Value (US$ Million) by Country, 2022 to 2032
  • Figure 40 : Latin America Market Value (US$ Million) Analysis by Country, 2017 to 2032
  • Figure 41 : Latin America Market Volume (Tons) Analysis by Country, 2017 to 2032
  • Figure 42 : Latin America Market Value Share (%) and BPS Analysis by Country, 2022 to 2032
  • Figure 43 : Latin America Market Y-o-Y Growth (%) Projections by Country, 2022 to 2032
  • Figure 44 : Latin America Market Value (US$ Million) Analysis by Drug Release, 2017 to 2032
  • Figure 45 : Latin America Market Volume (Tons) Analysis by Drug Release, 2017 to 2032
  • Figure 46 : Latin America Market Value Share (%) and BPS Analysis by Drug Release, 2022 to 2032
  • Figure 47 : Latin America Market Y-o-Y Growth (%) Projections by Drug Release, 2022 to 2032
  • Figure 48 : Latin America Market Value (US$ Million) Analysis by Distributional Channel, 2017 to 2032
  • Figure 49 : Latin America Market Volume (Tons) Analysis by Distributional Channel, 2017 to 2032
  • Figure 50 : Latin America Market Value Share (%) and BPS Analysis by Distributional Channel, 2022 to 2032
  • Figure 51 : Latin America Market Y-o-Y Growth (%) Projections by Distributional Channel, 2022 to 2032
  • Figure 52 : Latin America Market Attractiveness by Drug Release, 2022 to 2032
  • Figure 53 : Latin America Market Attractiveness by Distributional Channel, 2022 to 2032
  • Figure 54 : Latin America Market Attractiveness by Country, 2022 to 2032
  • Figure 55 : Europe Market Value (US$ Million) by Drug Release, 2022 to 2032
  • Figure 56 : Europe Market Value (US$ Million) by Distributional Channel, 2022 to 2032
  • Figure 57 : Europe Market Value (US$ Million) by Country, 2022 to 2032
  • Figure 58 : Europe Market Value (US$ Million) Analysis by Country, 2017 to 2032
  • Figure 59 : Europe Market Volume (Tons) Analysis by Country, 2017 to 2032
  • Figure 60 : Europe Market Value Share (%) and BPS Analysis by Country, 2022 to 2032
  • Figure 61 : Europe Market Y-o-Y Growth (%) Projections by Country, 2022 to 2032
  • Figure 62 : Europe Market Value (US$ Million) Analysis by Drug Release, 2017 to 2032
  • Figure 63 : Europe Market Volume (Tons) Analysis by Drug Release, 2017 to 2032
  • Figure 64 : Europe Market Value Share (%) and BPS Analysis by Drug Release, 2022 to 2032
  • Figure 65 : Europe Market Y-o-Y Growth (%) Projections by Drug Release, 2022 to 2032
  • Figure 66 : Europe Market Value (US$ Million) Analysis by Distributional Channel, 2017 to 2032
  • Figure 67 : Europe Market Volume (Tons) Analysis by Distributional Channel, 2017 to 2032
  • Figure 68 : Europe Market Value Share (%) and BPS Analysis by Distributional Channel, 2022 to 2032
  • Figure 69 : Europe Market Y-o-Y Growth (%) Projections by Distributional Channel, 2022 to 2032
  • Figure 70 : Europe Market Attractiveness by Drug Release, 2022 to 2032
  • Figure 71 : Europe Market Attractiveness by Distributional Channel, 2022 to 2032
  • Figure 72 : Europe Market Attractiveness by Country, 2022 to 2032
  • Figure 73 : East Asia Market Value (US$ Million) by Drug Release, 2022 to 2032
  • Figure 74 : East Asia Market Value (US$ Million) by Distributional Channel, 2022 to 2032
  • Figure 75 : East Asia Market Value (US$ Million) by Country, 2022 to 2032
  • Figure 76 : East Asia Market Value (US$ Million) Analysis by Country, 2017 to 2032
  • Figure 77 : East Asia Market Volume (Tons) Analysis by Country, 2017 to 2032
  • Figure 78 : East Asia Market Value Share (%) and BPS Analysis by Country, 2022 to 2032
  • Figure 79 : East Asia Market Y-o-Y Growth (%) Projections by Country, 2022 to 2032
  • Figure 80 : East Asia Market Value (US$ Million) Analysis by Drug Release, 2017 to 2032
  • Figure 81 : East Asia Market Volume (Tons) Analysis by Drug Release, 2017 to 2032
  • Figure 82 : East Asia Market Value Share (%) and BPS Analysis by Drug Release, 2022 to 2032
  • Figure 83 : East Asia Market Y-o-Y Growth (%) Projections by Drug Release, 2022 to 2032
  • Figure 84 : East Asia Market Value (US$ Million) Analysis by Distributional Channel, 2017 to 2032
  • Figure 85 : East Asia Market Volume (Tons) Analysis by Distributional Channel, 2017 to 2032
  • Figure 86 : East Asia Market Value Share (%) and BPS Analysis by Distributional Channel, 2022 to 2032
  • Figure 87 : East Asia Market Y-o-Y Growth (%) Projections by Distributional Channel, 2022 to 2032
  • Figure 88 : East Asia Market Attractiveness by Drug Release, 2022 to 2032
  • Figure 89 : East Asia Market Attractiveness by Distributional Channel, 2022 to 2032
  • Figure 90 : East Asia Market Attractiveness by Country, 2022 to 2032
  • Figure 91 : South Asia & Pacific Market Value (US$ Million) by Drug Release, 2022 to 2032
  • Figure 92 : South Asia & Pacific Market Value (US$ Million) by Distributional Channel, 2022 to 2032
  • Figure 93 : South Asia & Pacific Market Value (US$ Million) by Country, 2022 to 2032
  • Figure 94 : South Asia & Pacific Market Value (US$ Million) Analysis by Country, 2017 to 2032
  • Figure 95 : South Asia & Pacific Market Volume (Tons) Analysis by Country, 2017 to 2032
  • Figure 96 : South Asia & Pacific Market Value Share (%) and BPS Analysis by Country, 2022 to 2032
  • Figure 97 : South Asia & Pacific Market Y-o-Y Growth (%) Projections by Country, 2022 to 2032
  • Figure 98 : South Asia & Pacific Market Value (US$ Million) Analysis by Drug Release, 2017 to 2032
  • Figure 99 : South Asia & Pacific Market Volume (Tons) Analysis by Drug Release, 2017 to 2032
  • Figure 100 : South Asia & Pacific Market Value Share (%) and BPS Analysis by Drug Release, 2022 to 2032
  • Figure 101 : South Asia & Pacific Market Y-o-Y Growth (%) Projections by Drug Release, 2022 to 2032
  • Figure 102 : South Asia & Pacific Market Value (US$ Million) Analysis by Distributional Channel, 2017 to 2032
  • Figure 103 : South Asia & Pacific Market Volume (Tons) Analysis by Distributional Channel, 2017 to 2032
  • Figure 104 : South Asia & Pacific Market Value Share (%) and BPS Analysis by Distributional Channel, 2022 to 2032
  • Figure 105 : South Asia & Pacific Market Y-o-Y Growth (%) Projections by Distributional Channel, 2022 to 2032
  • Figure 106 : South Asia & Pacific Market Attractiveness by Drug Release, 2022 to 2032
  • Figure 107 : South Asia & Pacific Market Attractiveness by Distributional Channel, 2022 to 2032
  • Figure 108 : South Asia & Pacific Market Attractiveness by Country, 2022 to 2032
  • Figure 109 : MEA Market Value (US$ Million) by Drug Release, 2022 to 2032
  • Figure 110 : MEA Market Value (US$ Million) by Distributional Channel, 2022 to 2032
  • Figure 111 : MEA Market Value (US$ Million) by Country, 2022 to 2032
  • Figure 112 : MEA Market Value (US$ Million) Analysis by Country, 2017 to 2032
  • Figure 113 : MEA Market Volume (Tons) Analysis by Country, 2017 to 2032
  • Figure 114 : MEA Market Value Share (%) and BPS Analysis by Country, 2022 to 2032
  • Figure 115 : MEA Market Y-o-Y Growth (%) Projections by Country, 2022 to 2032
  • Figure 116 : MEA Market Value (US$ Million) Analysis by Drug Release, 2017 to 2032
  • Figure 117 : MEA Market Volume (Tons) Analysis by Drug Release, 2017 to 2032
  • Figure 118 : MEA Market Value Share (%) and BPS Analysis by Drug Release, 2022 to 2032
  • Figure 119 : MEA Market Y-o-Y Growth (%) Projections by Drug Release, 2022 to 2032
  • Figure 120 : MEA Market Value (US$ Million) Analysis by Distributional Channel, 2017 to 2032
  • Figure 121 : MEA Market Volume (Tons) Analysis by Distributional Channel, 2017 to 2032
  • Figure 122 : MEA Market Value Share (%) and BPS Analysis by Distributional Channel, 2022 to 2032
  • Figure 123 : MEA Market Y-o-Y Growth (%) Projections by Distributional Channel, 2022 to 2032
  • Figure 124 : MEA Market Attractiveness by Drug Release, 2022 to 2032
  • Figure 125 : MEA Market Attractiveness by Distributional Channel, 2022 to 2032
  • Figure 126 : MEA Market Attractiveness by Country, 2022 to 2032

Future Market Insights is the premier provider of market intelligence and consulting services, serving client in over 160 countries. FMI is headquartered in London, the global financial capital and has delivery centers in the U.S. and India. FMI's research and consulting services help businesses around the globe navigate the challenges in a rapidly evolving marketplace with confidence and clarity. Our customized and syndicated market research reports deliver actionable insights that drive sustainable growth. We continuously track emerging trends and events in a broad range of end industries to ensure that our clients prepare for the evolving needs of their customers. FMI's team of over 200 research analysts provides market intelligence at global, regional, and country levels. Our analysts are committed to provide independent insights, relying on our cognitive training modules, which conditions them to look at data objectively and unbiasedly. Others you can use from the file Allen just shared when those will be made live.

Future Markets Insights
Price: $5000

Become a Member

Already a member? Login here.

Have a Question? Ask Us.

Why BCC Research?

Every purchase provides access to:

  • Thousands of recently published reports from select publishers
  • Member Discounts of up to 50% on over 20,000 additional reports from all publishers
  • Our analysts and research concierge for all inquiries
Custom Research

Need a custom data table, graph or complete report? Tell us more.